Association of Esketamine use with mortality and clinical outcomes in patients with cancer-related depression: A target trial emulation (Chen, et al, 2026) “esketamine was associated with lower mortality and generally comparable safety outcomes in CRD, supporting its role as a potential therapeutic option for managing CRD.” https://pubmed.ncbi.nlm.nih.gov/42235877/ #esketamine #psychedelics #cancer #depression #ketaminesafety #mentalhealth

Ketamine and Esketamine in Neurology and Psychiatry: An Overview (Honnekeri, 2026) https://pubmed.ncbi.nlm.nih.gov/42117097/ “#ketamine and #esketamine represent a developing area in the treatment of TRD and highlight the broader emergence of interventional approaches in psychiatry“ #depression #mentalhealth #psychedelics

Cognitive Behavioral Therapy Following Esketamine for Major Depression and Suicidal Ideation for Relapse Prevention: The CBT-ENDURE Randomized Trial (Wilkinson, et al, 2026) https://pubmed.ncbi.nlm.nih.gov/42095692/ This study demonstrates the feasibility and the effectiveness of combining CBT with esketamine to reduce SI and prevent relapse in patients with MDSI. #ketamine #esketamine #psychedelics #cognitivebehavioraltherapy #depression #suicide #mentalhealth

A comprehensive review of the clinical progress of #esketamine From anesthesia to antidepressant therapy (Hu, et al, 2016) https://pubmed.ncbi.nlm.nih.gov/42065202/ Esketamine exerts its effects primarily through noncompetitive antagonism of N-methyl-D-aspartate receptors, leading to rapid modulation of glutamatergic signaling and neuroplasticity intravenous & intranasal esketamine have demonstrated rapid antidepressant effects in treatment-resistant depression, with response rates of 50% to 70% within 24 hours.

Inflammation and treatment strategies for suicidal behavior (2026) Individuals w/ suicidal behaviour exhibit elevated pro-inflammatory cytokines (interleukin-6, interleukin-1β, tumour necrosis factor-α), C-reactive protein (CRP), and chemokines in blood, CSF, and brain tissue. Several immunomodulatory treatments - including lithium, ketamine/esketamine show promise in reducing inflammation-linked to suicidal risk. #ketamine #esketamine #suicide #mentalhealth #psychedelics https://pubmed.ncbi.nlm.nih.gov/42059933/

#esketamine was used adjunctively with ongoing oral antidepressants. Intranasal esketamine in treatment-resistant #depression long-term dosing patterns and clinical outcomes in a 5-year observational study (Cuomo, et al, 2026) https://pubmed.ncbi.nlm.nih.gov/42052285/ associated with sustained symptom improvement and a favorable long-term safety profile among patients who continued treatment, with dosing evolving from induction to individualized maintenance schedules up to 260 weeks #ketamine #mentalhealth

Chronic Pain and Major Depression: Shared Psychological and Neurobiological Mechanism (Lee, et al, 2026) https://pubmed.ncbi.nlm.nih.gov/42036566/ #depression #pain #chronicpain #psychedelics #ketamine #mentalhealth #esketamine #rTMS

New Antidepressant Development in the Treatment of Depression (Spiti, et al, 2026) https://pubmed.ncbi.nlm.nih.gov/42036580/ #ketamine #psychedelics #depression #mentalhealth #esketamine

Psychedelics: Future Therapeutics in Major Depression? (Olivier, et al, 2026) https://pubmed.ncbi.nlm.nih.gov/42036582/ #ketamine #psychedelics #depression #mentalhealth #esketamine

Repeated intranasal #esketamine augmentation in treatment-resistant obsessive-compulsive disorder with comorbid major depressive disorder: a prospective case series (2026) “Repeated intranasal esketamine may offer a therapeutic window for patients with severe TR-OCD and comorbid MDD. These preliminary findings support further controlled studies to clarify its role, optimal administration, and integration with psychotherapy.” https://link.springer.com/article/10.1186/s12888-026-08119-5 #mentalhealth #ketamine #psychedelics #ocd